Hims & Hers Health heads into the post-earnings week in an awkward position: a stock that had rallied nearly 29% over the prior month gave back a large chunk of those gains in a single session, yet short sellers — despite holding one of the largest positions in the sector — are actually retreating rather than pressing their advantage.
The stock fell 14.1% on May 12 to close at $25.03, the direct response to a Q1 earnings miss that landed after the close on May 11. The one-day move was severe but not unprecedented: the prior earnings print in May 2026 also punished longs by more than 11% in a single day, and a February 2026 event produced a 3.9% decline before recovering 6.3% over the following week. The pattern across recent results is consistent — HIMS has not managed to clear its earnings bar cleanly.
Short interest in HIMS has been declining meaningfully, and that tells its own story. The short position peaked above 39% of the free float in late March, then fell steadily through April and into May. By May 12 it had dropped to roughly 30.5%, the lowest level in six weeks. The single-week change — down 8.6% in share terms — is the sharpest weekly cover seen since that March peak. With 29.3% of the float still short and the ORTEX short score holding at 68.3, the short side remains large by any standard; HIMS ranks in just the 6th percentile on the short score universe, meaning almost every other stock is less heavily shorted. Yet the direction of travel is clearly toward cover, not accumulation. The lending market is consistent with that read: cost to borrow remains low at 1.1% despite ticking up 22% on the week, and availability is tighter than loose — utilisation has climbed back to 89.9% after touching a 52-week high of 91.2% in late April — meaning most of the lendable pool is already committed, but borrowing is not expensive enough to force a cover cascade.
Options positioning leans constructive for bulls — or at least less bearish than usual. The put/call ratio has eased to 0.64, slightly below its 20-day average of 0.67, and is running near the bottom of the past year's range. The 52-week high of 1.52 puts the current reading in perspective: there is no particular rush to buy downside protection here, even after a double-digit earnings drop. Whether that reflects genuine conviction or simply a lack of hedging interest after the damage has already been done is worth noting.
The Street reaction to Q1 has been swift but measured. JPMorgan maintained its Overweight rating while trimming its target to $33 from $35 — the firm only initiated coverage in late April, so the cut lands early. Needham moved in the opposite direction, raising to $35 from $30 while holding its Buy. BofA lowered to $30 from $32, staying Neutral. Citi was a contrarian note, raising to $28 from $24 while also maintaining Neutral. The consensus has landed squarely on Hold across eleven analysts, with a mean price target of $26.60 — just 6% above the current price, a narrow spread that leaves little room for narrative. The bull case rests on the Novo Nordisk partnership unlocking a return to Rule-of-40 growth. Bears point to plateauing weight-loss revenues and regulatory risk in the compounded GLP-1 space, where HIMS built much of its recent growth. Forward EPS growth is high — ranked in the 92nd percentile for 12-month forward YoY increase — but near-term EPS surprise has been poor, sitting in just the 3rd percentile, which is precisely what the Q1 miss confirmed.
Insider activity provides a small piece of additional colour. The CFO sold shares on three separate occasions in April — totalling just under $1.55 million across trades at prices ranging from $25.90 to $29.96 — alongside smaller sales by the Chief Legal Officer. Net insider selling over the 90-day window reached $36 million in value. These are plan-driven sales rather than alarm signals on their own, but they add texture: insiders were systematically reducing exposure into the month's rally, at prices now above where the stock trades.
The next earnings date is June 11. Between now and then, the question is whether the short cover trend holds despite an uninspiring Q1, or whether the miss prompts fresh positioning to rebuild. The combination of a still-heavy short base, a Novo Nordisk partnership yet to fully prove itself in the numbers, and a Street consensus parked at Hold makes the next six weeks a period worth watching closely.
See the live data behind this article on ORTEX.
Open HIMS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
